LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

TIDMPXS

RNS Number : 7429K
Provexis PLC
26 April 2010


26 April 2010

Provexis PLC

Collaboration Agreement

Strengthened pipeline through tie-up with Institute of Food Research

Provexis plc ("Provexis" or the "Company"), the life-science business that
discovers, develops and licenses scientifically-proven functional food, medical
food and dietary supplement technologies, announces that it has entered into a
long-term research and development collaboration agreement with the Institute of
Food Research ("IFR") and Plant Bioscience Limited ("PBL') the technology
transfer company for IFR. As part of the agreement, Provexis has been granted
exclusive access to a portfolio of potentially high-value intellectual property
related to the treatment and reduction of systemic inflammation, from which it
intends to develop commercial products.

Professor Richard Mithen of IFR has developed a substantial body of work over
twenty years in the area of isothiocyanates for the reduction of risk of certain
major cancers. More recent work, some in collaboration with Provexis, has led to
the discovery of a broader effect in other areas of systemic inflammation,
including cardiovascular inflammation. As a result patents for a novel extract
were filed jointly by Provexis, IFR and PBL in 2008.

This new collaboration gives Provexis a broad range of exclusive rights to the
background and joint intellectual property. The partners will collaborate to
develop the science, with major areas including clinical trials, extract
development, further IP development, regulatory clearances and
commercialisation. The first phase of the project gives Provexis the exclusive
option to license the technology from IFR and PBL and if successful in this
phase, Provexis intend to move to fully in-license the technology rights.

Initially the Company, supported by IFR's substantial research, will focus on
developing commercial products targeting the reduction of cardiovascular
inflammation. A second, longer-term objective is to develop technologies
designed to mitigate the risk of certain major cancers.

Stephen Moon, CEO of Provexis said:

"The collaboration with IFR is a further step in the continued expansion of
Provexis and its product pipeline. The initial work to develop a cardiovascular
claim and product complements our already recognised expertise in the heart
health arena and in the longer term we feel we are ideally positioned to develop
technologies that work to reduce the risk of some major cancers. This new
venture further strengthens our pipeline and is an important element in creating
long term shareholder value."

seems to be heading down, next stop 3p?

slipping under the radar, PXS is having a stonking day (no, not stinking!) and is +36% (a whole 1.39p!) on very heavy volume

Something a foot me thinks. Hopefully news of DSM deal signing. And further news

Further news out today in the form of the accounts.

Headlines for me:

Revenue - 14k
Loss - 1.7m

Fees of 1.2m to raise the last lump of cash!!

Director salaries (Moon - 200k) & share options.

SP heading sub 3p.

it's always good to see the directors looking after themselves properly .... heaven forbid the company should be making a profit first

Those results were announced by PXS on the 1st June (Prelims), so there is nothing new. There is no subsequent, worthwhile, significant news though. Will PXS have something staggering to tell us on or before their AGM on 9th September? Or will we just be staggered?! :0)

perhaps the directors will be asked to explain how they manage to justify paying themselves so handsomely when the company is smaller than our little private one here - and we make a consistent profit!

Hmm, yes, the shareholders have been Mooned!

I posted only Moon's renumeration, the total package for all directors is a staggering 500k approx; for a company that managed revenues of 14k.

They work on the same principles as the banks obviously!

wonder if i can be bothered to get off my arse and go down the road to make a nuisance of myself in Reading

You give um hell from me cyners....thata boy.,. I can only drink so much of the stuff and the sp hasn't shifted...

but have your bowels?

lol

Have shares in this one and in profit, is it worth holding on to them as the SP just not picking up.

Mrs B
i do hope you wont mind me asking but is this your first post?
have you read the other 53 pages?
it really is not allowed to offer advice on here to anyone. even one such as yourself. only opinions are allowed, and i also would be reluctant to offer you my opinion on this one. be it good or not so good.
whatever you decide i wish you well.
regards to you
jkd

AGM/EGM thursday.

Tick tock, Not long to wait now! Deals, Deals, Deals!

it would be more than a little rash to get excited let alone overexcited, but over 26m already traded this morning against a daily average of just 5m

=============

just 10 minutes later and volume is up to 32m, but curiously, sp has only risen 0.2p